Results for the quarter ended 31.12.2024
Awaiting price reaction for this filing.
Sangam Health Care Products reported weak Q3 FY25 numbers with net sales falling to Rs. 286.65 lakhs, down about 19% from Rs. 353.29 lakhs in the same quarter last year and down 21% sequentially from Rs. 361.96 lakhs in Q2 FY25. Operating profit collapsed to Rs. 10.88 lakhs from Rs. 55.71 lakhs a year ago, and net profit dropped roughly 80% YoY, pulling EPS down to Rs. 0.07 from Rs. 0.37. For the nine-month period, revenue slipped marginally to Rs. 984.67 lakhs while profit after tax fell to Rs. 26.22 lakhs from Rs. 84.06 lakhs. A critical disclosure notes that the company was delisted by BSE effective 28 November 2024 due to non-compliance of certain requirements, though the company states it is in the process of getting listed again. The statutory auditors issued an unqualified limited review report.
Shareholders face a triple concern: sharp year-on-year revenue and profit decline, severe margin compression, and the stock's delisting status which severely limits liquidity and price discovery. Until the company successfully re-lists and demonstrates a recovery in operating performance, this remains a high-risk situation for investors.